Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 71335-2852

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 71335-2852). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing guanfacine plasma concentration (ng/mL) over 24 hours. It shows time (hours) on the x-axis and plasma concentration on the y-axis. Two lines represent extended-release guanfacine 1 mg once daily and immediate-release guanfacine 1 mg once daily, illustrating differences in their plasma concentration profiles over time.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A fold change and 90% confidence interval chart showing the pharmacokinetic effects on Guanfacine extended-release. It compares changes in Cmax and AUC relative to reference when co-administered with CYP3A4/5 inhibitors (Ketoconazole, Fluconazole), CYP3A4 inducers (Rifampin, Efavirenz), Oral Methylphenidate, and Lisdexamfetamine Dimesylate, using both human data and computer simulations.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC comparing oral methylphenidate and lisdexamfetamine dimesylate relative to a reference. The x-axis represents change relative to reference, ranging from 0.0 to 2.0. Data points are indicated with markers on the plot.*
FDA Label Image

Figure4.jpg (Figure4)

Figure4.jpg (Figure4)
A line graph illustrating treatment failure percentage over time in days, comparing placebo and SPD503 groups. The x-axis represents time to treatment failure in days, and the y-axis shows treatment failure percentage. The graph includes a solid line for placebo and a dashed line for SPD503, showing differing treatment failure rates over approximately 200 days.*
FDA Label Image

Label (Lbl713352852)

Label (Lbl713352852)
Label for guanfacine extended-release tablets, USP, 2 mg strength. The label indicates 100 tablets in the package, labeled by Bryant Ranch Prepack and manufactured by Apotex Inc. Includes storage instructions and a QR code for package insert and dosage information.*
FDA Label Image

Spd503-chemical-stucture (Spd503 Chemical Stucture)

Spd503-chemical-stucture (Spd503 Chemical Stucture)
Chemical structure diagram showing the molecular formula of guanfacine hydrochloride, indicating atoms and bonds including chlorine (Cl) and hydrogen chloride (HCl) components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.